POXEL Announces Growing Sales of TWYMEEG in Japan for 2024

Biopharmaceutical company POXEL SA has reported promising sales figures for TWYMEEG® in Japan, marking a 17% increase in the fourth quarter of 2024 compared to the previous quarter. Sales have increased by an impressive 154% compared to the same period in 2023. Despite this performance, annual sales forecasts have been revised downward by its partner, Sumitomo Pharma, to 7.9 billion yen, from the 11.3 billion initially forecast.

Poxel will receive royalties of 10% of net sales for the year 2024, in addition to a one-time payment of 500 million yen. Beyond this year, double-digit royalties are expected to increase. Sumitomo has taken measures to mitigate the impact of its internal restructuring on the commercialization of TWYMEEG®.